Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,558 questions in 115 reviews · Vascular
current versionsNo studies 346 · 22.2%Ungraded 90 · 5.8%Very low 281 · 18%Low 477 · 30.6%Moderate 313 · 20.1%High 51 · 3.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Avoralstat vs placebo Change in number of HAE attacks (per week) · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | 2 studies · 134 participants | Low |
C1 esterase inhibitor vs placebo or active control Disability (any validated scale) (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
C1 esterase inhibitor vs placebo or active control Adverse events (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | RR 1.03 [0.84, 1.27] | 1 study · 44 participants | Moderate |
Plasma‐derived C1 esterase inhibitor vs placebo or active control Risk of HAE attacks (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Plasma‐derived C1 esterase inhibitor vs placebo or active control Change in number of HAE attacks (per week) · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | 1 study · 71 participants | Low |
Plasma‐derived C1 esterase inhibitor vs placebo or active control Mortality (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Plasma‐derived C1 esterase inhibitor vs placebo or active control Serious adverse events (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | RR 0.54 [0.09, 3.1] | 1 study · 71 participants | Very low |
Plasma‐derived C1 esterase inhibitor vs placebo or active control Quality of lifeAngioedema Quality of Life Score(lower score is better) (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | 1 study · 31 participants | Low |
Plasma‐derived C1 esterase inhibitor vs placebo or active control Disability(any validated scale) (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Plasma‐derived C1 esterase inhibitor vs placebo or active control Adverse events(during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | RR 1.05 [0.78, 1.42] | 1 study · 71 participants | Low |
Nanofiltered C1 esterase inhibitor vs placebo or active control Risk of HAE attacks (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Avoralstat vs placebo Mortality (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Nanofiltered C1 esterase inhibitor vs placebo or active control Change in number of HAE attacks (per week) · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | 1 study · 22 participants | Very low |
Nanofiltered C1 esterase inhibitor vs placebo or active control Mortality (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Nanofiltered C1 esterase inhibitor vs placebo or active control Serious adverse events (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Nanofiltered C1 esterase inhibitor vs placebo or active control Quality of lifestandardised mean difference (lower is better) (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | 1 study · 16 participants | Very low |
Nanofiltered C1 esterase inhibitor vs placebo or active control Disability standardised mean difference (lower is better) (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | 1 study · 16 participants | Very low |
Nanofiltered C1 esterase inhibitor vs placebo or active control Adverse events (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human C1 esterase inhibitor vs placebo or active control Risk of HAE attacks (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human C1 esterase inhibitor vs placebo or active control Change in number of HAE attacks (per week) · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | 1 study · 32 participants | Very low |
Recombinant human C1 esterase inhibitor vs placebo or active control Mortality (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human C1 esterase inhibitor vs placebo or active control Serious adverse events (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | RR 1.5 [0.06, 34.66] | 1 study · 29 participants | Very low |
Avoralstat vs placebo Serious adverse events (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | RR 0.33 [0.01, 7.8] | 1 study · 24 participants | Very low |
Recombinant human C1 esterase inhibitor vs placebo or active control Quality of lifestandardised mean difference(during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human C1 esterase inhibitor vs placebo or active control Disability(any validated scale)(during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human C1 esterase inhibitor vs placebo or active control Adverse events(during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | RR 1.39 [0.71, 2.7] | 1 study · 29 participants | Low |
Lanadelumab vs placebo or active control Risk of HAE attacks (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Lanadelumab vs placebo or active control Change in number of HAE attacks (per week) · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | 2 studies · 83 participants | Low |
Lanadelumab vs placebo or active control Mortality (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Lanadelumab vs placebo or active control Serious adverse events (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | RR 0.88 [0.08, 10.39] | 2 studies · 162 participants | Low |
Lanadelumab vs placebo or active control Quality of lifestandardised mean difference(lower is better)(during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | 1 study · 68 participants | Low |
Lanadelumab vs placebo or active control DisabilityStandardised mean difference(lower is better)(during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | 1 study · 64 participants | Low |
Lanadelumab vs placebo or active control Adverse events(during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | RR 1.07 [0.77, 1.47] | 2 studies · 158 participants | Low |
Avoralstat vs placebo Quality of lifeAngioedema Quality of Life scale (lower score is better)(during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | 2 studies · 93 participants | Moderate |
Avoralstat vs placebo Disability (any validated scale) (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Avoralstat vs placebo Adverse events (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | RR 0.85 [0.62, 1.16] | 1 study · 24 participants | Low |
Berotralstat vs placebo or active control Risk of HAE attacks (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | RR 0.63 [0.39, 1] | 1 study · 37 participants | Low |
Berotralstat vs placebo or active control Change in number of HAE attacks (per week) · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | 3 studies · 130 participants | Low |
Ultrasound guidance vs landmark method First‐pass success of cannulation · adults undergoing peripheral venous cannulation classed as difficulta Ultrasound guidance versus landmark method for peripheral venous cannulation in adults (2022) · Cochrane | RR 1.5 [1.15, 1.95] | 10 studies · 815 participants | Low |
Ultrasound guidance vs landmark method Pain NRS: from 0 to 10, where 10 is maximum pain · adults undergoing peripheral venous cannulation classed as moderately difficulta Ultrasound guidance versus landmark method for peripheral venous cannulation in adults (2022) · Cochrane | no estimate extracted | 1 study · 401 participants | Low |
Ultrasound guidance vs landmark method Procedure time for first‐pass cannulation (seconds) · adults undergoing peripheral venous cannulation classed as moderately difficulta Ultrasound guidance versus landmark method for peripheral venous cannulation in adults (2022) · Cochrane | no estimate extracted | 1 study · 401 participants | High |
Ultrasound guidance vs landmark method Number of cannulation attempts · adults undergoing peripheral venous cannulation classed as moderately difficulta Ultrasound guidance versus landmark method for peripheral venous cannulation in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Ultrasound guidance vs landmark method Patient satisfaction NRS from 0 to 10 or 4‐step Likert scaleThe higher the score the higher the level of satisfaction · adults undergoing peripheral venous cannulation classed as moderately difficulta Ultrasound guidance versus landmark method for peripheral venous cannulation in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Ultrasound guidance vs landmark method Overall complications · adults undergoing peripheral venous cannulation classed as moderately difficulta Ultrasound guidance versus landmark method for peripheral venous cannulation in adults (2022) · Cochrane | RR 0.83 [0.38, 1.82] | 1 study · 401 participants | Moderate |
Ultrasound guidance vs landmark method First‐pass success of cannulation · adults undergoing peripheral venous cannulation classed as easya Ultrasound guidance versus landmark method for peripheral venous cannulation in adults (2022) · Cochrane | RR 0.89 [0.85, 0.94] | 1 study · 596 participants | High |
Ultrasound guidance vs landmark method Overall success of cannulation · adults undergoing peripheral venous cannulation classed as easya Ultrasound guidance versus landmark method for peripheral venous cannulation in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Ultrasound guidance vs landmark method Pain NRS: from 0 to 10, where 10 is maximum pain · adults undergoing peripheral venous cannulation classed as easya Ultrasound guidance versus landmark method for peripheral venous cannulation in adults (2022) · Cochrane | no estimate extracted | 1 study · 596 participants | Moderate |
Ultrasound guidance vs landmark method Procedure time for first‐pass cannulation (seconds) · adults undergoing peripheral venous cannulation classed as easya Ultrasound guidance versus landmark method for peripheral venous cannulation in adults (2022) · Cochrane | no estimate extracted | 1 study · 596 participants | High |
Ultrasound guidance vs landmark method Number of cannulation attempts · adults undergoing peripheral venous cannulation classed as easya Ultrasound guidance versus landmark method for peripheral venous cannulation in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Ultrasound guidance vs landmark method Overall success of cannulation · adults undergoing peripheral venous cannulation classed as difficulta Ultrasound guidance versus landmark method for peripheral venous cannulation in adults (2022) · Cochrane | RR 1.4 [1.1, 1.77] | 10 studies · 670 participants | Very low |